Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX

Cwm LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 218.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 83,724 shares of the company’s stock after buying an additional 57,435 shares during the period. Cwm LLC owned approximately 0.08% of Neurocrine Biosciences worth $11,753,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of NBIX. Geneos Wealth Management Inc. boosted its stake in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. WPG Advisers LLC acquired a new stake in Neurocrine Biosciences in the first quarter worth $32,000. MAI Capital Management boosted its position in shares of Neurocrine Biosciences by 101.2% during the second quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after purchasing an additional 165 shares in the last quarter. True Wealth Design LLC grew its holdings in shares of Neurocrine Biosciences by 1,215.4% in the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after buying an additional 316 shares during the period. Finally, Huntington National Bank increased its position in shares of Neurocrine Biosciences by 26.4% in the 2nd quarter. Huntington National Bank now owns 604 shares of the company’s stock valued at $76,000 after buying an additional 126 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the sale, the insider directly owned 43,405 shares of the company’s stock, valued at $6,929,608.25. The trade was a 9.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director George J. Morrow sold 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the transaction, the director owned 7,068 shares of the company’s stock, valued at approximately $1,013,339.16. This represents a 67.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 43,866 shares of company stock valued at $6,570,237 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $145.26 on Monday. The company has a market cap of $14.48 billion, a PE ratio of 34.75, a PEG ratio of 0.95 and a beta of 0.27. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18. The stock has a 50-day simple moving average of $147.05 and a 200 day simple moving average of $138.89.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, beating the consensus estimate of $1.58 by $0.59. The firm had revenue of $794.90 million for the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The business’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 EPS. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NBIX. Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Royal Bank Of Canada raised their price target on Neurocrine Biosciences from $160.00 to $180.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. HC Wainwright increased their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Needham & Company LLC raised their target price on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.25.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.